{"id":"W3005184972","doi":"10.1016/j.jaad.2020.01.072","title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":70,"is_retracted":false,"has_abstract":false,"ca_institutions":"Lynde Centre for Dermatology","funders":"Janssen Biotech; Ortho Dermatologics; LEO Pharma; Sanofi Genzyme; GlaxoSmithKline; Australian Renewable Energy Agency; MedImmune; Kyowa Hakko Kirin; Sun Pharma; Dermira; UCB Pharma; Valeant Pharmaceuticals International; Medac; AbbVie; Novartis; Celgene; Regeneron Pharmaceuticals; University of Connecticut; Amgen; Meiji Seika Pharma; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Almirall","keywords":"Medicine; Apremilast; Scalp; Placebo; Dermatology; Multicenter study; Double blind; Psoriasis; Randomized controlled trial; Adverse effect; Multicenter trial; Surgery; Internal medicine; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004798126,0.0002445551,0.00228607,0.0001950633,0.00005761304,0.000002741872,0.0005357621,0.0001345174,0.000006188603],"category_scores_gemma":[0.0003623018,0.0001270544,0.0002893733,0.0004020203,0.0007238524,0.0000701427,0.0001729069,0.0003909156,7.638896e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002220199,"about_ca_system_score_gemma":0.00009334968,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005271819,"about_ca_topic_score_gemma":0.00001073787,"domain_scores_codex":[0.9961419,0.001587511,0.001681345,0.0002131795,0.0001473383,0.0002287874],"domain_scores_gemma":[0.9952639,0.001091939,0.003261879,0.0001891156,0.0001405457,0.00005263221],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9578608,0.001629606,0.02818504,0.00003646286,0.002185532,0.000002943772,0.003308084,0.0004891792,0.004694508,0.00001081003,0.0001145514,0.001482505],"study_design_scores_gemma":[0.9380207,0.001266871,0.02625804,0.0001781333,0.00112851,0.00007982094,0.0008047987,0.00003496819,0.03205474,0.000007125979,0.00004287217,0.0001234448],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944545,0.0003489253,0.00002363958,0.002897441,0.0001054517,0.002028222,0.0001094297,0.000002855835,0.00002954305],"genre_scores_gemma":[0.999532,0.0001167673,0.0001278722,0.000167941,0.00001213667,0.00001645739,0.000002356432,0.00001361854,0.000010808],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02736023,"threshold_uncertainty_score":0.518113,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01734425170394657,"score_gpt":0.2760336491930642,"score_spread":0.2586893974891176,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}